Effects of phosphodiesterase (PDE) inhibitors on human ether-a-go-go related gene (hERG) channel activity

Journal of Applied Toxicology

Volumn 27, Issue 1, 2007, Pages 78-85

  Yunomae, Kiyokazu ^a   Ichisaki, Satoko ^a   Matsuo, Junko ^a   Nagayama, Shinichi ^a   Fukuzaki, Koichiro ^a   Nagata, Ryoichi ^a   Kito, Go ^a  

^a SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

Author keywords

hERG, CHO K1 cell; Patch clamp technique; PDE inhibitors; PKA; Vesnarinone; Vinpocetine

Indexed keywords

8 BROMO CYCLIC AMP; 9 (2 HYDROXY 3 NONYL)ADENINE; AMRINONE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIPYRIDAMOLE; FORSKOLIN; MILRINONE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PHOSPHODIESTERASE INHIBITOR; PIPERANOMETOZINE; POTASSIUM CHANNEL HERG; ROLIPRAM; STAUROSPORINE; VINPOCETINE; ZAPRINAST;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; GENE ACTIVITY; GENETIC TRANSFECTION; NONHUMAN; PATCH CLAMP; PHOSPHORYLATION; PRIORITY JOURNAL;

ADENINE; AMRINONE; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME ACTIVATORS; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; ISOENZYMES; MEMBRANE POTENTIALS; MILRINONE; PATCH-CLAMP TECHNIQUES; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PROTEIN KINASE INHIBITORS; PURINONES; QUINOLINES; ROLIPRAM; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; VINCA ALKALOIDS;

EID: 33846606083     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1201     Document Type: Article

References (34)

1. Allen RA, Merriman MW, Perry MJ, Owens RJ. 1999. Development of a recombinant cell-based system for the characterisation of phosphodiesterase 4 isoforms and evaluation of inhibitors. Biochem. Pharmacol. 57: 1375-1382.
2. Asanoi H, Sasayama S, Kameyama T, Ishizaka S, Iuchi K. 1989. Sustained inotropic effects of a new cardiotonic agent. OPC-8212 in patients with chronic heart failure. Clin. Cardiol. 12: 133-138.
3. Busch AE, Varnum MD, North RA, Adelman JP. 1992. An amino acid mutation in a potassium channel that prevents inhibition by protein kinase C. Science 255: 1705-1707.
4. + channels by hypoxia in smooth muscle cells isolated from the pig coronary artery. J. Physiol. 483: 29-39.
5. Dustan Sarazan R, Crumb WJ Jr, Beasley CM Jr, Emmick JT, Ferguson KM, Strnat CA, Sausen PJ. 2004. Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5-sildenafil, tadalafil, and vardenafil. Eur. J. Pharmacol. 502: 163-167.
6. Ehses JA, Pelech SL, Pederson RA, McIntosh CH. 2002. Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J. Biol. Chem. 277: 37088-37097.
7. Fan JS, Plade P. 1998. Perforated patch recording with beta-escine. Pflugers Arch. 436: 1021-1023.
8. Ficker E, Kuryshev YA, Dennis AT, Obejero-Paz C, Wang L, Hawryluk P, Wible BA, Brown AM. 2004. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol. Pharmacol. 66: 33-44.
9. Fu LY, Wang F, Chen XS, Zhou HY, Yao WX, Xia GJ, Jiang MX. 2003. Perforated patch recording of L-type calcium current with beta-escin in guinea pig ventricular myocytes. Acta Pharmacol. Sin. 24: 1094-1098.
10. + channels expressed in Xenopus oocytes. J. Physiol. 495: 681-688.
11. 2+ sensitizing action. 1st communication: phosphodiesterase III inhibitory effect and class III antiarrhythmic effect in guinea-pig heart. Arzneimittelforschung 49: 398-406.
12. Horn R, Marty A. 1988. Muscarinic activation of ionic currents measured by a new whole-cell recording method. J. Gen. Physiol. 92: 145-159.
13. Iijima T, Taira N. 1987. Membrane current changes responsible for the positive inotropic effect of OPC-8212, a new positive inotropic agent, in single ventricular cells of the guinea pig heart. J. Pharmacol. Exp. Ther. 240: 657-662.
14. + channels by vesnarinone. Mol. Pharmacol. 60: 244-253.
15. + channels expressed in a mammalian cell line. J. Pharmacol. Exp. Ther. 294: 339-346.
16. Kiehn J, Karle C, Thomas D, Yao X, Brachmann J, Kubler W. 1998. HERG potassium channel activation is shifted by phorbol esters via protein kinase A-dependent pathways. J. Biol. Chem. 273: 25285-25291.
17. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, Brown AM, Kang J, Chen XL, Sawamura K, Reynolds W, Rampe D. 2005. Pentamidine-induced long QT syndrome and block of hERG trafficking. J. Pharmacol. Exp. Ther. 312: 316-323.
18. Liang BT. 1997. Protein kinase C-mediated preconditioning of cardiac myocytes: role of adenosine receptor and KATP channel. Am. J. Physiol. 273: H847-H853.
19. + currents by protein kinase C and adenosine. Implications for ischemic preconditioning. Circ. Res. 78: 443-454.
20. Mizuno H, Adachi H, Kimura J, Sawa Y, Kakiki M, Lansdell K, Saito M, Kerns WD. 2003. Cardiovascular assessment of ER-118585, a selective phosphodiesterase 5 inhibitor. Biol. Pharm. Bull. 26: 1661-1667.
21. Pearlstein RA, Vaz RJ, Kang J, Chen XL, Preobrazhenskaya M, Shchekotikhin AE, Korolev AM, Lysenkova LN, Miroshnikova OV, Hendrix J, Rampe D. 2003. Characterization of hERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg. Med. Chem. Lett. 13: 1829-1835.
22. Rapundalo ST, Lathrop DA, Harrison SA, Beavo JA, Schwartz A. 1988. Cyclic AMP-dependent and cyclic AMP-independent actions of a novel cardiotonic agent, OPC-8212. Naunyn Schmiedebergs Arch. Pharmacol. 338: 692-698.
23. Ridley JM, Milnes JT, Witchel HJ, Hancox JC. 2004. High affinity hERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656. Biochem. Biophys. Res. Commun. 325: 883-891.
24. Robison GA, Butcher RW, Sutherland EW. 1968. Cyclic AMP. Annu. Rev. Biochem. 37: 149-174.
25. Seamon KB, Padgett W, Daly JW. 1981. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc. Natl Acad. Sci. USA 78: 3363-3367.
26. Singh TJ, Roth C, Gottesman MM, Pastan IH. 1981. Characterization of cyclic AMP-resistant Chinese hamster ovary cell mutants lacking type I protein kinase. J. Biol. Chem. 256: 926-932.
27. 2+/calmodulin-stimulated cyclic AMP phosphodiesterase (PDE1) activity in Chinese hamster ovary cells (CHO) by phorbol 12-myristate 13-acetate and by the selective overexpression of protein kinase C isoforms. Biochem. J. 310: 975-982.
28. Taira N, Endoh M, Iijima T, Satoh K, Yanagisawa T, Yamashita S, Maruyama M, Kawada M, Monta T, Wada Y. 1984. Mode and mechanism of action of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC-8212), a novel positive inotropic drug, on the dog heart. Arzneimittelforschung 34: 347-355.
29. Thomas D, Wei Z, Karle CA, Kathofer S, Schols W, Kubler W, Kiehn J. 1999. Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A. J. Biol. Chem. 274: 27457-27462.
30. + current. Circulation 96: 3696-3703.
31. Walsh KB, Kass RS. 1988. Regulation of a heart potassium channel by protein kinase A and C. Science 242: 67-69.
32. Wible BA, Hawryluk P, Ficker E, Kuryshev YA, Kirsch G, Brown AM. 2005. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J. Pharmacol. Toxicol. Methods 52: 136-145.
33. Yamashita S, Hosokawa T, Kojima M, Mori T, Yabuuchi Y. 1984. In vitro and in vivo studies of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)- 1-piperazinyl]-2(1H)-quinolinone (OPC-8212), a novel positive inotropic drug, in various animals. Arzneimittelforschung 34: 342-346.
34. Zhang W, Thomas D, Karle CA, Kathofer S, Schenkel J, Kreye VA, Ficker E, Wible BA, Kiehn J. 2002. Protein kinase A-mediated phosphorylation of HERG potassium channels in a human cell line. Chin. Med. J. 115: 668-676.